No, it should not. A medication which causes the structural change of the brain will not be approved by FDA.
Answered 4/19/2022
0 views
It modifies neurochemistry, but does not alter anatomy. There is not focal or diffuse atrophy secondary to riisperidone.
Answered 4/20/2022
0 views
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question